Coherus Biosciences (CHRS) PT Lowered to $25 at JPMorgan
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.26 -3.08%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 6 | New: 39
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 6 | New: 39
Join SI Premium – FREE
JPMorgan lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $25.00 (from $32.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherus Oncology hires Oppenheimer to sell biosimilar assets
- LTM Ltd (LTM:IN) PT Raised to INR4,600 at HSBC
- JPMorgan Double Downgrades Estun Automation Co Ltd (002747:CH) to Underweight
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
